April 2010

The NIPER, Mohali will appoint a few more scientists and faculty on ad-hoc basis in the next three-six months to extend all required services to the small and medium sector pharma companies under the aegis of the Small and Medium Pharmaceutical Industry Centre (SMPIC) and make it fully useful for the struggling industry.

Taking vitamin C and E supplements starting in early pregnancy does not reduce the risk for the hypertensive disorders and their complications that occur during pregnancy, according to a study by a National Institutes of Health research network.

Kylin Therapeutics, Inc, a leading RNAi company, announced that they have received patent from the US Patent and Trademark Office (US PTO).

Assam, Rajasthan and Tamil Nadu have been awarded as the Best Performing States in implementing National Rural Health Mission (NRHM) which has completed five years.

[adsense:336x280:8701650588]

In a novel agreement, two global pharma majors have planned to make available their top-selling pneumonia vaccines at one-eighth of the market rates to save lives of poor children in developing countries.

Every day, 4,384 people, mostly children below the age of five, die due to preventable pneumococcal diseases, primarily pneumonia and meningitis. Most of these deaths, 1.6 million in a year, occur in some of the world’s poorest countries.

Shanghai will be playing host to UBM International Media events CPhI, P-MEC, ICSE and BioPh From June 2 to 4. While CPhI will be focusing on intermediates and APIs markets, ICSE is for contract services and P-MEC exhibitors offer a complete range of pharma machinery and equipment. BioPh is aimed at those who provide bio-solutions for pharma.

Last year’s events attracted more than 23,000 attendees from 102 countries and more than 1,600 exhibitors, 127 of which were international companies.

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received approval to advance to the next phase of its New Zealand phase-II human clinical trial with its groundbreaking Diabecell. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its Diabecell implants.